Bortezomib for the treatment of non-Hodgkin’s lymphoma

Advances in the treatment of hematologic malignancies using immunoconjugates

(2014) M. C. Palanca-Wessels et al.   BLOOD

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

(2014) J. E. Chang et al.   BLOOD

Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study

(2014) Andrew M. Evens et al.   BRITISH JOURNAL OF HAEMATOLOGY

Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies

(2014) Tadeusz Robak et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib

(2013) K. M. Kortuem et al.   BLOOD

A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas

(2013) Andrew M. Evens et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

(2013) Girija Dasmahapatra et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib-Rituximab Versus Rituximab

(2013) B. Coiffier et al.   CLINICAL CANCER RESEARCH

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

(2013) Andre Goy et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma

(2013) Z-X Yan et al.   LEUKEMIA

Targeting pathological B cell receptor signalling in lymphoid malignancies

(2013) Ryan M. Young et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proteasome inhibitors in mantle cell lymphoma

(2012) Beata Holkova et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

Management of indolent lymphoma: Where are we now and where are we going

(2012) Matthew A. Lunning et al.   BLOOD REVIEWS

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

(2012) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

(2012) Philippe Moreau et al.   CLINICAL PHARMACOKINETICS

Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial

(2012) Seok Jin Kim et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d’Etude des Lymphomes de l’Adulte (GELA)

(2012) Vincent Ribrag et al.   EUROPEAN JOURNAL OF CANCER

Molecular pathogenesis of mantle cell lymphoma

(2012) Pedro Jares et al.   JOURNAL OF CLINICAL INVESTIGATION

Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma

(2012) Rebecca L. Elstrom et al.   LEUKEMIA & LYMPHOMA

Anti-CD20 Antibody Therapy for B-Cell Lymphomas

(2012) David G. Maloney   NEW ENGLAND JOURNAL OF MEDICINE

Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside

(2012) A. R. Mato et al.   ONCOLOGIST

The Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 Predicts Response to Chemotherapy and Determines the Efficacy of Proteasome Inhibitors in Diffuse Large B-Cell Lymphoma

(2011) Ana Mozos et al.   AMERICAN JOURNAL OF PATHOLOGY

Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS

(2011) R. Houot et al.   ANNALS OF ONCOLOGY

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

(2011) J. W. Friedberg et al.   BLOOD

Peripheral T-cell lymphoma

(2011) F. M. Foss et al.   BLOOD

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study

(2011) Julie E. Chang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

(2011) Ticiana B. Leal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

(2011) B. Holkova et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non-Hodgkin Lymphoma

(2011) J. Gerecitano et al.   CLINICAL CANCER RESEARCH

Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma

(2011) M. A. Weniger et al.   CLINICAL CANCER RESEARCH

Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkinʼs Lymphoma

(2011) Andrzej Hellmann et al.   CLINICAL PHARMACOKINETICS

Bortezomib for previously untreated multiple myeloma

(2011) Michel Delforge   EXPERT OPINION ON PHARMACOTHERAPY

Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma

(2011) W. Lamm et al.   HAEMATOLOGICA

Novel Therapeutics for Aggressive Non-Hodgkin's Lymphoma

(2011) Daruka Mahadevan et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

(2011) Nathan Fowler et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group

(2011) Laurie H. Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance

(2011) Amy M. Ruschak et al.   JNCI-Journal of the National Cancer Institute

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

(2011) Bertrand Coiffier et al.   LANCET ONCOLOGY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)

(2011) C. Tom Kouroukis et al.   LEUKEMIA & LYMPHOMA

Bortezomib Induces Nuclear Translocation of I B  Resulting in Gene-Specific Suppression of NF- B-Dependent Transcription and Induction of Apoptosis in CTCL

(2011) A. Juvekar et al.   MOLECULAR CANCER RESEARCH

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)

(2010) A. Conconi et al.   ANNALS OF ONCOLOGY

Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells

(2010) S. H. Olejniczak et al.   BLOOD

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

(2010) P. Perez-Galan et al.   BLOOD

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

(2010) S. Bringhen et al.   BLOOD

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

(2010) Agathoclis Agathocleous et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

(2010) Robert A. Baiocchi et al.   CANCER

BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress

(2010) Girija Dasmahapatra et al.   CANCER BIOLOGY & THERAPY

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

(2010) Donna E. Reece et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells

(2010) R. Rao et al.   CLINICAL CANCER RESEARCH

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

(2010) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma

(2010) L. Paoluzzi et al.   CLINICAL CANCER RESEARCH

Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study

(2010) Karthik Venkatakrishnan et al.   CLINICAL THERAPEUTICS

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

(2010) B. Mohty et al.   HAEMATOLOGICA

Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma

(2010) F. Baran-Marszak et al.   HAEMATOLOGICA

Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

(2010) Jia Ruan et al.   JOURNAL OF CLINICAL ONCOLOGY

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

(2010) Guido Cavaletti et al.   LEUKEMIA & LYMPHOMA

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

(2010) Sundar Jagannath et al.   LEUKEMIA RESEARCH

PRDM1 Is Required for Mantle Cell Lymphoma Response to Bortezomib

(2010) S. Desai et al.   MOLECULAR CANCER RESEARCH

Aggressive Lymphomas

(2010) Georg Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

(2009) N. Di Bella et al.   BLOOD

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

(2009) Owen A. O’Connor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

(2009) John Gerecitano et al.   BRITISH JOURNAL OF HAEMATOLOGY

PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells

(2009) S. Bhalla et al.   CLINICAL CANCER RESEARCH

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkinʼs Lymphoma or Multiple Myeloma

(2009) David I. Quinn et al.   CLINICAL PHARMACOKINETICS

A phase II study of bortezomib in patients with MALT lymphoma

(2009) M. Troch et al.   HAEMATOLOGICA

Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma

(2009) Sven de Vos et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

(2009) Steven P. Treon et al.   JOURNAL OF CLINICAL ONCOLOGY

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

(2009) Q-L Zhang et al.   LEUKEMIA

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

(2008) A. Goy et al.   ANNALS OF ONCOLOGY

PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor

(2008) W.-L. Zhao et al.   BLOOD

Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells

(2008) Y. Dai et al.   CLINICAL CANCER RESEARCH

Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study

(2008) Asher Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

The NF-κB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs

(2008) Mario I. Vega et al.   LEUKEMIA & LYMPHOMA

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways

(2008) Edgar Gil Rizzatti et al.   LEUKEMIA & LYMPHOMA

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

(2008) David T Yang et al.   Molecular Cancer

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE